Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Encephalitis
Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
April 15th, 2009
Intercell AG (VSE: ICLL) announced that its new vaccine to prevent Japanese Encephalitis, IXIARO(R), has been approved by the European Commission. The approval by the European Union, the first for a vaccine to prevent the disease, provides formal market authorization in all 27 member states as well as Norway and Iceland. "The European approval of IXIARO marks a crucial milestone in Intercell's evolution as one of the leading independent vaccine development companies with a vaccine marketed," said Intercell's Chief Executive Officer Gerd Zettlmeissl. "For the first time, both civilians and members of the military across Europe will have access to a safe and effective...
Source: Vaccine Weekly (2009-04-15)
|
